라코사미드

그림문자(GHS)

• 그림문자(GHS)

  

• 신호 어

  Danger

• 유해·위험 문구

  H225：고인화성 액체 및 증기

  H319：눈에 심한 자극을 일으킴

• 예방조치문구

  P210：열·스파크·화염·고열로부터 멀리하시오 - 금연 하시오.

  P280：보호장갑/보호의/보안경/안면보호구를 착용하시오.

  P305+P351+P338：눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.

라코사미드 화학적 특성, 용도, 생산

• 개요

  Although epilepsy is a neurological disorder with varying etiology and severity, the common feature is unprovoked, recurring seizures. Whether classified as generalized, involving both cerebral hemispheres, or partial with only localized portions of brain participation at onset, effective treatment relies on accurate assessment of syndrome type to optimally decrease the frequency, duration, and severity of seizures. The latest weapon against partial onset epilepsy is lacosamide, formerly known as harkoseride and erlosamide. The data also indicate that lacosamide binds to collapsing response mediator protein 2 (CRMP2); CRMP2 is involved in neuronal differentiation, control of axonal outgrowth, and possibly epileptogenesis. Furthermore, lacosamide is heralded as having a dual mode of action as it has also displayed efficacy against diabetic neuropathy, possibly as a result of stabilization of neuronal hyperexcitability. Currently,lacosamide is approved as adjunctive treatment of partial onset seizures in patients 17 years or older and is in development as a monotherapy for epilepsy and for neuropathic pain.

• 화학적 성질

  White to Off-White Solid

• 역사

  Lacosamide, a functionalized amino acid, has become an important third-generation antiepileptic drug after systematic drug development. Its discovery stemmed from a 1996 study at the University of Houston, where researchers hypothesized that modified amino acids might have potential applications in epilepsy treatment. Against this backdrop, Dr. Harold Cohen and his team, while studying the mechanism of action of biotin, noticed its structural similarity to certain neuroactive compounds, inspiring them to synthesize a series of functionalized amino acids and screen for their anticonvulsant activity. With the support of the National Institute of Neurological Diseases and Stroke (NINDS) anticonvulsant drug screening program, lacosamide (then codenamed SPM 927) was identified as a promising candidate drug due to its potent anticonvulsant properties.
  In 2000, Schwarz Pharma in Germany collaborated with Harris FRC to advance the preclinical and clinical development of lacosamide. Based on substantial clinical evidence, lacosamide's marketing application was approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) in 2007. In September 2008, the drug was officially approved for marketing in the European Union, and in October of the same year, it was approved in the United States under the brand name Vimpat®. In November 2018, lacosamide tablets were approved for marketing in China, becoming the first third-generation antiepileptic drug approved in China. Subsequently, oral solutions and other dosage forms were also launched. To date, the clinical application of lacosamide has expanded from its initial role as adjunctive therapy for adult partial epilepsy to monotherapy, and is used to treat a wider range of pediatric patients and primary generalized tonic-clonic epilepsy.

• 용도

  A potent anticonvulsant.

라코사미드 공급 업체

Global(535)Suppliers

라코사미드 관련 검색